Pentair vs Xylem
PNR and XYL side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PNR and XYL compare
Xylem is the larger company, worth 2.0 times as much as Pentair ($21.7B against $10.7B).
On earnings, Pentair is cheaper: it trades at 17.7× trailing earnings, against 20.9× for Xylem.
Xylem grew revenue faster over the last twelve months (1.9% versus −3.9% for Pentair).
Pentair keeps more of each dollar of sales as profit, with a net margin of 15.4% compared with 11.9% at Xylem.
Both pay dividends: Pentair yields 1.2% and Xylem 1.8%.
Xylem scores higher on the StockData Score (24 against 17 for Pentair), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PNR | XYL |
|---|---|---|
| Size and price | ||
| Market cap | $10.7B | $21.7B |
| Share price | $66.88 | $94.65 |
| Change, 1 year | −35.9% | −33.7% |
| Change, 5 years | −11.1% | −22.8% |
| Beta (5Y) | 0.34 | 0.18 |
| Employees | 9,000 | 22K |
| StockData Score | ||
| Total score | 17 | 24 (better) |
| Valuation score | 5 | 6 (better) |
| Growth score | 3 | 4 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 17.7× (better) | 20.9× |
| P/S | 2.7× | 2.4× (better) |
| P/B | – | 2.1× |
| EV/EBITDA | 15.5× (better) | 17.4× |
| P/FCF | 16.5× (better) | 23.6× |
| PEG | 1.62 | 0.81 (better) |
| FCF yield | 6.1% (better) | 4.2% |
| Fair value | $82.06 | $119.17 |
| Margin of safety | 18.5% | 20.6% (better) |
| Growth | ||
| Revenue growth (TTM) | −3.9% | 1.9% (better) |
| Revenue growth, 5Y average | 6.7% | 13.1% (better) |
| Net income growth (TTM) | −6.4% | 14.1% (better) |
| EPS growth (TTM) | −4.6% | 16.2% (better) |
| EPS growth, 5Y average | 13.1% | 22.9% (better) |
| Profitability | ||
| Gross margin | 41.2% (better) | 39.8% |
| Operating margin | 19.6% (better) | 15.1% |
| Net margin | 15.4% (better) | 11.9% |
| FCF margin | 16.3% (better) | 10.2% |
| Return on equity | – | 10.1% |
| Return on invested capital | – | 9.0% |
| Financial health | ||
| Debt / equity | – | 0.28 |
| Net debt / EBITDA | 1.81 | 1.59 (better) |
| Interest coverage | – | 36.1× |
| Current ratio | 1.47 (better) | 1.39 |
| Altman Z-score | 4.00 (better) | 3.11 |
| Piotroski F-score | 9 (better) | 7 |
| Dividends and buybacks | ||
| Dividend yield | 1.2% | 1.8% (better) |
| Payout ratio | 28.1% | 37.4% |
| Years of dividend growth | 6 | 13 (better) |
| Dividend growth, 5Y average | 5.6% | 9.0% (better) |
| Buyback yield | 3.7% | 7.3% (better) |
| Shareholder yield | 5.0% | 9.1% (better) |
| Ownership | ||
| Held by institutions | 95.7% | 94.9% |
| Held by insiders | 0.84% | 0.20% |
| Insider net buying, 12 months | −$2.1M | $625K (better) |
| Short interest, % of float | 4.8% | 3.8% |
Go deeper
- PNR stock overview
- PNR income statement
- PNR valuation and score
- XYL stock overview
- XYL income statement
- XYL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.